UNSPSC 51383316: Felbinac ethyl

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978ZPS989U, chemically known as acetic acid, (4-biphenylyl)-, ethyl ester, but more generally known as felbinac ethyl, which bears US NIH Compound Identifier 26436. European Medicines Agency schedules felbinac ethyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07527MIG.

Most nations, for tariff purposes, schedule felbinac ethyl under HS 29163900. SMILES: CCOC(=O)CC1CCC(CC1)C2CCCCC2.

UNSPSC 51383316 Felbinac ethyl is a Commodity code that in practice covers pharmaceutical products and related health-care supplies procured by state and local health agencies, though the recent opportunities tagged to this code diverge significantly from the narrow chemical name. State and local governments solicit under this code for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and direct-to-manufacturer prescription program capabilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administering on behalf of participating state and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other members). The mix reflects both direct county procurement and coordinated multi-jurisdiction purchasing through established cooperative frameworks.

Recent activity spans the South, Midwest, and multi-state cooperative regions. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building with all shipping costs included in bids. The Texas HHS Commission issued a Request for Information (HHS0017013) on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity with self-insured employer and health plan clients outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with proposals due March 26, 2026, requiring manufacturers to provide detailed product specifications, NDC codes, and compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act, with the resulting agreements effective July 1, 2026. The cooperative purchasing vehicle demonstrates the multi-jurisdiction reach of pharmaceutical procurement under this code.